Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Spinal Muscular Atrophy Type II: later-stage trial registry
A small indexed set (3 trials) with no open enrollment listed right now.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · none currently recruiting · #5,209 of 28,707 conditions by registered trial count
Spinal Muscular Atrophy Type II: 3 US clinical trials tracked, none currently recruiting.
Spinal Muscular Atrophy Type II is the subject of 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Novartis Gene Therapies, running 1 of these trials.
Enrollment posture brief
Registry condition spinal-muscular-atrophy-type-ii
OPEN 0 | RECR 0% | LATE 1 | EARLY 0 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Spinal Muscular Atrophy Type II has no open enrollment in this registry pull (3 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Spinal Muscular Atrophy Type II on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Spinal Muscular Atrophy Type II is recruiting below its size-band peers.
0 of 3 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
3 total, page 1 of 1
Spinraza in Adult Spinal Muscular Atrophy
Washington University School of Medicine
NCT03709784
Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi
Novartis Gene Therapies
NCT04042025
Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy - Upper Limb
Marco Capogrosso
NCT06300996
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Spinal Muscular Atrophy Type II records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Spinal Muscular Atrophy Type II trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Spinal Muscular Atrophy Type II page
3 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Spinal Muscular Atrophy Type II trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Novartis Gene Therapies sponsors the most Spinal Muscular Atrophy Type II trials on record, review their full trial history before evaluating a specific study. See Novartis Gene Therapies's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Spinal Muscular Atrophy Type II condition card totals 3 registered trials; most-linked intervention One time survey; top US site state Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.